Your browser is no longer supported. Please, upgrade your browser.
La Jolla Pharmaceutical Company
Index- P/E12.08 EPS (ttm)0.32 Insider Own1.68% Shs Outstand27.50M Perf Week-15.43%
Market Cap102.66M Forward P/E- EPS next Y0.00 Insider Trans132.88% Shs Float27.14M Perf Month1.30%
Income12.40M PEG0.92 EPS next Q0.04 Inst Own67.90% Short Float1.03% Perf Quarter-10.78%
Sales74.50M P/S1.38 EPS this Y66.40% Inst Trans-2.89% Short Ratio2.77 Perf Half Y-17.06%
Book/sh-2.63 P/B- EPS next Y-103.90% ROA13.70% Target Price4.00 Perf Year-17.76%
Cash/sh- P/C- EPS next 5Y13.20% ROE-15.90% 52W Range3.35 - 7.85 Perf YTD0.26%
Dividend- P/FCF- EPS past 5Y11.60% ROI39.00% 52W High-50.45% Beta2.27
Dividend %- Quick Ratio3.70 Sales past 5Y99.50% Gross Margin79.60% 52W Low16.12% ATR0.32
Employees59 Current Ratio4.10 Sales Q/Q46.20% Oper. Margin24.80% RSI (14)42.48 Volatility12.03% 7.41%
OptionableYes Debt/Eq- EPS Q/Q80.90% Profit Margin16.70% Rel Volume4.77 Prev Close3.89
ShortableYes LT Debt/Eq- Earnings- Payout0.00% Avg Volume101.31K Price3.89
Recom3.00 SMA20-8.89% SMA50-4.90% SMA200-9.44% Volume0 Change0.00%
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral
Nov-25-19Downgrade SunTrust Buy → Hold
Jan-23-19Upgrade JP Morgan Underweight → Neutral
Jan-14-19Upgrade Jefferies Underperform → Hold
Feb-12-18Downgrade Jefferies Buy → Underperform
Jan-25-18Reiterated Chardan Capital Markets Neutral $90 → $100
Dec-26-17Reiterated SunTrust Buy $57 → $65
Dec-22-17Reiterated SunTrust Buy $67 → $65
Dec-22-17Reiterated H.C. Wainwright Buy $62 → $91
Dec-21-17Initiated H.C. Wainwright Buy $62
Dec-08-17Downgrade JP Morgan Overweight → Underweight
Aug-30-17Initiated JP Morgan Overweight $36
Feb-27-17Reiterated SunTrust Buy $38 → $57
Jun-22-16Initiated SunTrust Buy $30
May-24-16Initiated Lake Street Buy $25
Sep-08-15Reiterated Chardan Capital Markets Buy $60 → $80
Jul-07-15Reiterated Chardan Capital Markets Buy $54 → $60
May-11-15Reiterated H.C. Wainwright Buy $29 → $20
Apr-21-15Initiated Oppenheimer Outperform $43
Mar-20-15Reiterated H.C. Wainwright Buy $20 → $29
Nov-17-21 08:00AM  
Nov-04-21 10:05AM  
Nov-01-21 03:01PM  
Oct-25-21 10:46AM  
Oct-04-21 12:51AM  
Sep-10-21 08:00AM  
Aug-05-21 10:15AM  
Jul-29-21 03:05PM  
Jul-26-21 05:01AM  
Jun-10-21 04:57AM  
May-18-21 06:22AM  
May-07-21 10:05AM  
Mar-11-21 03:12AM  
Mar-08-21 10:45AM  
Jan-16-21 01:41AM  
Jan-12-21 08:15AM  
Dec-28-20 03:08AM  
Dec-23-20 08:56AM  
Dec-02-20 10:15PM  
Nov-13-20 07:07AM  
Nov-09-20 05:35PM  
Oct-19-20 03:30PM  
Oct-09-20 10:49AM  
Aug-25-20 08:31AM  
Aug-21-20 02:02PM  
Aug-06-20 08:30AM  
Jul-28-20 04:16PM  
Jun-24-20 07:30AM  
Jun-22-20 12:14PM  
Jun-14-20 07:00AM  
Jun-10-20 04:22PM  
May-21-20 08:30AM  
May-07-20 12:55PM  
May-06-20 08:41AM  
May-04-20 09:55AM  
Apr-27-20 12:31PM  
Apr-13-20 08:30AM  
Apr-07-20 08:30AM  
Apr-06-20 08:30AM  
Apr-03-20 08:30AM  
Apr-02-20 08:30AM  
Mar-13-20 08:00AM  
Mar-02-20 09:55AM  
Feb-24-20 12:30PM  
Jan-27-20 08:23AM  
Jan-18-20 05:09PM  
Jan-15-20 07:00AM  
Jan-09-20 08:00AM  
Dec-13-19 03:07PM  
Nov-26-19 08:06AM  
Nov-25-19 09:04AM  
Nov-15-19 09:52AM  
Nov-12-19 06:35PM  
Nov-11-19 09:59AM  
Oct-16-19 10:32AM  
Aug-29-19 09:00AM  
Aug-16-19 02:38PM  
Aug-14-19 03:36PM  
Aug-01-19 09:35AM  
Jul-30-19 11:53AM  
Jul-23-19 09:00AM  
Jul-01-19 08:39AM  
Jun-28-19 06:30AM  
Jun-11-19 11:55AM  
Jun-07-19 02:02PM  
Jun-06-19 09:00AM  
May-22-19 01:49PM  
May-06-19 06:25PM  
May-02-19 10:33AM  
Apr-29-19 01:25PM  
Apr-24-19 09:00AM  
Mar-11-19 07:30AM  
Mar-08-19 02:49PM  
Mar-07-19 04:01PM  
Mar-06-19 08:56AM  
Mar-05-19 07:24AM  
Mar-04-19 06:33PM  
Feb-25-19 04:04PM  
Feb-14-19 07:18PM  
Feb-05-19 08:20AM  
Jan-18-19 07:00AM  
Jan-10-19 07:00AM  
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAMSAY DAVID ADirectorNov 17Buy4.237,50031,72575,500Nov 19 05:05 PM
TANG KEVIN CDirectorJun 01Buy4.4759,092263,93110,049,224Jun 01 06:42 PM
TANG KEVIN CDirectorMay 27Buy4.47185,928831,7629,990,132Jun 01 06:42 PM
TANG KEVIN CDirectorMay 26Buy4.26166,932710,7639,804,204May 26 04:56 PM
TANG KEVIN CDirectorMay 25Buy3.79127,379482,7349,637,272May 26 04:56 PM
RAMSAY DAVID ADirectorMay 24Buy3.4920,00069,83868,000May 26 06:28 PM
TANG KEVIN CDirectorMay 24Buy3.68104,403384,2349,509,893May 26 04:56 PM